Survival after breast cancer in women with type 2 diabetes using antidiabetic medication and statins: a retrospective cohort study

Authors

  • Mayu Hosio Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland
  • Elina Urpilainen Department of Obstetrics and Gynaecology, PEDEGO Research Unit, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland
  • Ari Hautakoski Research Unit of Mathematical Sciences, University of Oulu, Oulu, Finland;
  • Mikko Marttila Orion Corporation, Espoo, Finland
  • Martti Arffman Service System Research Unit, Finnish Institute for Health and Welfare, Helsinki, Finland
  • Reijo Sund Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland
  • Anne Ahtikoski Cancer and Translational Medicine Research Unit, Department of Pathology, Oulu University Hospital and University of Oulu, Oulu, Finland
  • Ulla Puistola Department of Obstetrics and Gynaecology, PEDEGO Research Unit, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland;
  • Peeter Karihtala Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland; ;Department of Oncology, University of Helsinki and Helsinki University Comprehensive Cancer Center, Helsinki, Finland
  • Arja Jukkola Department of Oncology and Radiotherapy, Cancer Centre Tampere, Tampere University Hospital, Tampere, Finland; ;Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
  • Esa Läärä Research Unit of Mathematical Sciences, University of Oulu, Oulu, Finland

DOI:

https://doi.org/10.1080/0284186X.2020.1769858

Abstract

Background: We assessed survival of breast cancer in women with type 2 diabetes (T2D) treated with metformin, other types of antidiabetic medication (ADM) and statins.

Materials and Methods: The study cohort consisted of women with T2D and diagnosed with breast cancer in Finland in 1998─2011. Mortality rates from breast cancer and other causes were analysed by Cox models, and adjusted hazard ratios (HRs) with 95% confidence intervals (Cls) were estimated in relation to the use of different types of medication.

Results: The final cohort consisted of 3,533 women. No clear evidence was found for breast cancer mortality being different in metformin users (HR 0.86, 95% Cl 0.63–1.17), but their other-cause mortality appeared to be lower (HR 0.73, 95% Cl 0.55–0.97) in comparison with women using other types of oral ADM. Other-cause mortality was higher among insulin users (HR 1.45, 95% Cl 1.16–1.80) compared with users of other oral ADMs, other than metformin. Prediagnostic statin use was observed to be associated with decreased mortality from both breast cancer (HR 0.76, 95% Cl 0.63–0.92) and other causes (HR 0.75, 95% Cl 0.64–0.87).

Conclusions: We did not find any association between ADM use and disease-specific mortality among women with T2D diagnosed with breast cancer. However, interestingly, prediagnostic statin use was observed to predict reduced mortality from breast cancer and other causes. We hypothesise that treating treatment practices of T2D or hypercholesterolaemia of breast cancer patients might affect overall prognosis of women diagnosed with breast cancer and T2D.

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2020-09-01

How to Cite

Hosio, M. ., Urpilainen, E. ., Hautakoski, A. ., Marttila, M. ., Arffman, M. ., Sund, R. ., … Läärä, E. . (2020). Survival after breast cancer in women with type 2 diabetes using antidiabetic medication and statins: a retrospective cohort study. Acta Oncologica, 59(9), 1110–1117. https://doi.org/10.1080/0284186X.2020.1769858

Issue

Vol. 59 No. 9 (2020): Acta Oncologica

Section

Articles